Case Report: Secondary bilateral parkinsonism and dystonia treated with dronabinol [version 2; peer review: 1 approved, 1 approved with reservations]

Natalia Szejko1-3, Florian Burger4, Victoria Sidoroff5, Gregor K. Wenning5

1Department of Neurology, Medical University of Warsaw, Warsaw, 02091, Poland
2Department of Bioethics, Medical University of Warsaw, Warsaw, 02091, Poland
3Division of Neurocritical Care, Department of Neurology, Yale University, New Haven, Connecticut, 06519, USA
4District Hospital Kufstein, Kufstein, Austria
5Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria

Abstract
Drug abuse may damage basal ganglia that are essential for planning and execution of movements. We report a 38-year old patient with ischemic lesions of the basal ganglia presenting with bilateral painful dystonia and parkinsonism caused by polyintoxication. Dronabinol resulted in improvement of pain and gait disturbance, suggesting a novel therapeutic strategy in these challenging patients.

Keywords
dronabinol, secondary parkinsonism, dystonia, intoxication, ischemic stroke
Introduction

Drug abuse is an important health issue, not only affecting the social surrounding of a patient but also the cerebral integrity. Besides a number of different somatic abnormalities provoked by an intoxication, certain drugs may damage areas of the brain, such as basal ganglia or cortex, which are essential for the movement onset and coordination1.2.

In this case report, we present a 38-year-old male patient with a long-lasting drug history, including the abuse of cocaine, cannabinoids, benzodiazepines, opiates, methadone and amphetamines. As a result of the multi-intoxications induced bilateral ischemic lesions to the basal ganglia, the patient presented with secondary bilateral dystonia and parkinsonism. It is not certain whether the cause of ischemia could be related to any specific drug or combinations thereof. Cocaine and its metabolites are known to cause cerebral vasospasm that could lead to ischemic infarctions in the whole brain7,8 or can provoke haemorrhagic stroke9. Heroin causes ischemia more often in the globus pallidus10. Amphetamines are known as the second most frequent cause of ischemia after cocaine, especially in younger patients due to their vasoconstrictive effect11,12. Although it is not clear whether cannabinoids and its metabolites can cause cerebrovascular events, there is evidence that cannabis can increase the risk for haemorrhagic stroke12,13. Opioids may not have a direct toxic impact on the neurons, but ischemic lesions or necrosis can be triggered by recurrence of drug-induced hypoxia1.

The aim of this case report is to show the possible use of dronabinol for a multi-intoxicated patient with ischemia of the basal ganglia in order to temper his pain and improve gait.

Case report

We present a case of a 27-year-old Caucasian man who was admitted to the Intensive Care Unit (ICU) after multi-intoxication. Drug screening on admission identified the following substances: opiates, benzodiazepines, cannabinoids, crack cocaine, methadone and amphetamine. Due to the history of drug abuse he was unemployed. During the first days the patient was in coma, with Glasgow Coma Scale of 5 points. After slow amelioration of his status he presented with severe dysarthria, dysphagia, as well as bilateral parkinsonism and dystonia of his extremities. The neurological examination showed a bilateral positive Babinski sign, global rigidity in all extremities as well as symmetrical hyperreflexia. Furthermore, he suffered from high fever that resolved after treatment with benzodiazepines. Therefore, vegetative symptoms accompanying the patient on submission were interpreted as drug withdrawal syndrome. Both, CT and MRI showed bilateral hypoxemiastic infarction of the basal ganglia and boundary zone (Figure 1). Those changes could be the consequence of the mixed intoxication or could be attributed to only one harmful substance, especially crack cocaine or amphetamine. During the hospitalization he developed a tracheobronchitis and respiratory insufficiency due to acute respiratory distress syndrome (ARDS). Moreover, because of severe dysphagia he was nourished via percutaneous endoscopic gastrostomy. Further consequences of his primary condition included post ischemic epilepsy treated with levetiracetam (1000mg). After six months of intensive care, the patient was discharged from hospital.

During the next five years the patient was treated with levodopa (titrated up to 800mg/day), apomorphine (up to 100 mg/day), selegiline (10mg/day) and baclofen (75mg/day). Further up-titration of levodopa was not possible because of subsequent side effects, such as hallucinations. Due to sleeping problems and agitation he was treated with trazodone (150mg/day) and quetiapine (250mg/day). The substitution dose of buprenorphine 20mg/day was tapered off constantly to keep the patient in a drug naive state. Nonetheless, he showed aggressive behaviour under the influence of alcohol and was admitted to psychiatric ward several times due to delusional disorder and recurrent addictive behaviours. After several months of psychiatric treatment, his addiction and hallucinations resolved. In spite of intense treatment, both parkinsonism as well as dystonia persisted for years and additional symptoms such as generalized pain as well as gait disturbances occurred.

During the examination in our outpatient clinic, 11 years after the hospitalization in the ICU, the patient was still experiencing moderate dysarthria, bilateral dystonia of all extremities, bilateral akinetiform parkinsonism, camptocormia and freezing. Due to those symptoms and increased anxiety as well as painful dystonia as well as unsuccessful treatment with evidence-based agents the patient was treated with dronabinol by his psychiatrist (capsules slowly up titrated to 20mg/day).

After two months of dronabinol treatment, the patient reported subjective improvement of the dystonic pain and a
We examined the patient at two timepoints: after two months and after two months of dronabinol therapy. Importantly, the medication used at both timepoints remained stable, which excludes confounding contribution of other agents. Results of clinical assessments after two and six months of dronabinol administration are shown in Table 1. The baseline Unified Parkinson’s Disease Rating Scale and Unified Dystonia Rating Scale results cannot be provided as the data were not collected. Although the patient reported the subjective improvement of his symptoms, this was not confirmed in the neurological examination or in the UPDRS and UDRS assessments. Particularly, there was no minimal clinically important differences for UPDRS nor UDRS, although there was an improvement in sleep quality according to ESS. It can therefore be concluded that dronabinol had major analgesic and calming effect and, as a consequence, also improved sleep and general performance. Although he self-reported gait amelioration, it is not clear whether the patient exhibited any motor improvement.

Discussion
While there is some evidence that cannabis-based medicine (CBM) could improve both motor and non-motor symptoms in Parkinson’s disease (PD)\cite{8,9}, the effectiveness of CBM in secondary parkinsonism as well as dystonia is unknown. Recently, Pehall et al.\cite{10} reported the potential efficacy of nabulone for PD patients with disturbing non-motor symptoms, which appears to be driven by positive effects on anxious mood and night-time sleep problems. Moreover, a number of other open label studies and case reports demonstrated efficacy of CBM in treatment of movement disorders\cite{11,12}. Small randomized trials in Tourette syndrome confirmed efficacy of tetrahydrocannabinol (THC) for tic reduction\cite{14,15}. Therefore, CBM might be a useful therapeutic alternative for therapy resistant patients with movement disorders. However, systematic reviews and meta-analysis in this group of patients demonstrated conflicting results, due to methodological limitations of studies with CBM\cite{16,17}.

In the case of our patient, his condition improved only subjectively, but this was not confirmed with objective neurological testing. Moreover, the use of cannabinoids in this case is controversial as the patient had a positive medical

<table>
<thead>
<tr>
<th>Scale</th>
<th>Examination after two months</th>
<th>Examination after six months</th>
</tr>
</thead>
<tbody>
<tr>
<td>UPDRS I</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>UPDRS II</td>
<td>18</td>
<td>14</td>
</tr>
<tr>
<td>UPDRS III</td>
<td>26</td>
<td>24</td>
</tr>
<tr>
<td>UPDRS IV</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>H-Y</td>
<td>2.5</td>
<td>2.5</td>
</tr>
<tr>
<td>Schwab and England</td>
<td>80%</td>
<td>90%</td>
</tr>
<tr>
<td>UDRS</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>PDSS-2</td>
<td>1</td>
<td>12</td>
</tr>
<tr>
<td>ESS</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>BDI</td>
<td>11</td>
<td>10</td>
</tr>
</tbody>
</table>

UPDRS, Unified Parkinson’s Disease Rating Scale; H-Y, Modified Hoehn and Yahr Staging; PDSS-2, Parkinson Disease Sleep Scale-2; UDRS, Unified Dystonia Rating Scale; ESS, Epworth Sleepiness Scale; BDI, Beck Depression Inventory.
history for cannabis misuse. Additionally, long-term effectiveness should also be investigated with accuracy. Potential psychotic effects could be dangerous, therefore the dosage in our patient was slowly increased. Nevertheless, safety profile of CBM in movement disorders reported in previous studies was favorable, with the most common side effects being sedation, dizziness and sensation of “being high”. Finally, no baseline assessments, prior to dronabinol administration, were available. Results of international randomized, double-blind controlled trials with CBM in PD might offer more scientific rationales for discussion of potential usefulness of CBM in other movement disorders.

Data availability
All data underlying the results are available as part of the article and no additional source data are required.

Consent
Written informed consent for publication of their clinical details and clinical images was obtained from the patient.

References

The authors reported an interesting and challenging case of secondary bilateral parkinsonism and dystonia. Treatment with dronabinol resulted in improvement of pain and gait disturbance.

**Major concerns:**

1. Pain improvement was not supported by score change in a specific scale.

2. Likewise, improvement in gait disturbance was not supported by consistent UPDRS/UDRS score change. Subjective improvement of gait was attributed to moderate (subjective?) improvement of freezing of gait, with less falls. However, UPDRS does not assess freezing of gait, and a scale specifically assessing freezing of gait was not administered.

3. The authors should provide a quantitative assessment of the number/time of falls occurred before and after dronabinol.

In conclusion, this report neither support nor discourage the therapeutic use of dronabinol in secondary movement disorders.

**Minor points:**

1. Introduction:

I would suggest changing the introduction starting with a paragraph that briefly describes dystonia and parkinsonism. Some relevant references to be cited:

   - Kojovic *et al.* (2013)
   - Defazio *et al.* (2020)
   - Korczyn *et al.* (2015)
   - Belvisi *et al.* (2020)
2. Case report:
   ○ Please better describe the neurological examination, in particular please provide more information on dystonia. Was the cranial region involved? Does the patient develop a sensory trick?
   ○ Please correct this typo providing the right timing info: “We examined the patient at two timepoints: after two months and after two months of dronabinol therapy.”

3. Discussion:
   ○ I would suggest adding a short paragraph describing the possible mechanisms of the ischemic event and the relationship between the drug abuse and the MRI findings.

References

Is the background of the case's history and progression described in sufficient detail?
Partly

Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?
Partly

Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?
Partly

Is the case presented with sufficient detail to be useful for other practitioners?
Yes

*Competing Interests:* No competing interests were disclosed.

*Reviewer Expertise:* Movement disorders

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.
Author Response 04 Aug 2021

Natalia Szejko, Medical University of Warsaw, Warsaw, Poland

Thank you so much for reviewing our manuscript. We provide answers to reviewer’s suggestions below:

**Major points:**
- **Pain improvement was not supported by score change in a specific scale.**
  - **Response:** We do agree that this would provide more objective results regarding the pain improvement, however, at the moment of examination none pain scales were administered. Unfortunately, we cannot provide these data.
- **Likewise, improvement in gait disturbance was not supported by consistent UPDRS/UDRS score change. Subjective improvement of gait was attributed to moderate (subjective?) improvement of freezing of gait, with less falls. However, UPDRS does not assess freezing of gait, and a scale specifically assessing freezing of gait was not administered.**
  - **Response:** We also agree with this suggestion, however, similarly to the previous point, we did not use any scale to assess the freezing of gait.
- **The authors should provide a quantitative assessment of the number/time of falls occurred before and after dronabinol.**
  - **Response:** Again, this was not inquired during the patient’s visits, but the patient reported about general improvement in this domain. Moreover, now it is impossible to gain this information due to recall bias.
- **In conclusion, this report neither support nor discourage the therapeutic use of dronabinol in secondary movement disorders.**
  - **Response:** We agree with this statement and reformulated the conclusions appropriately: “All in all, all positive effects were subjective and the final conclusion about the effectiveness of dronabinol cannot be reached.”

**Minor points:**
- **Introduction:** I would suggest changing the introduction starting with a paragraph that briefly describes dystonia and parkinsonism. Some relevant references to be cited: Kojovic et al. (2013), Defazio et al. (2020), Korczyn et al. (2015), Belvisi et al. (2020)
  - **Response:** We appreciate this suggestion and have included a new paragraph in the introduction: “However, it is clear that primary and secondary movement disorders have different pathophysiology and, therefore, require different treatments [4-6].”
- **Case report:** Please better describe the neurological examination, in particular please provide more information on dystonia. Was the cranial region involved? Does the patient develop a sensory trick?
  - **Response:** We also appreciate this suggestion and have explained it in more detail: “In particular, dystonia was limited to dystonic posturing of the fingers and painful dystonia of the toes.”
- **Please correct this typo providing the right timing info:** “We examined the patient at two
timepoints: after two months and after two months of dronabinol therapy.”

- **Response:** We have corrected this typo accordingly and now it states: “We examined the patient at two timepoints: after two months and after six months of dronabinol therapy”.

- **Discussion:** I would suggest adding a short paragraph describing the possible mechanisms of the ischemic event and the relationship between the drug abuse and the MRI findings.

- **Response:** Thank you, we have included paragraph describing possible pathophysiology of these findings: “In case of our patient the suspected mechanism is suspected to be vasospasm provoked by drug abuse that, in turn, provoked ischemia and, finally, abnormal pattern of movements”.

**Competing Interests:** No competing interests were disclosed.

---

Reviewer Report 27 October 2020

https://doi.org/10.5256/f1000research.30251.r73627

© 2020 Lopez-Sendon Moreno J. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Jose Luis Lopez-Sendon Moreno
Neurology Department, Hospital Ramón y Cajal, Madrid, Spain

I believe that the amendments are correct and the article is ready for indexing.

**Is the background of the case's history and progression described in sufficient detail?**
Yes

**Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?**
Yes

**Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?**
Yes

**Is the case presented with sufficient detail to be useful for other practitioners?**
Yes

**Competing Interests:** No competing interests were disclosed.
Reviewer Expertise: Clinical research. Cannabinoids.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Jose Luis Lopez-Sendon Moreno
Neurology Department, Hospital Ramón y Cajal, Madrid, Spain

The authors describe an interesting case about a patient with secondary dystonia and parkinsonism and an apparent improvement with dronabinol. The case is relevant since it provides insight into the treatment of a disabling condition. Also, the use of cannabinoids in the setting of movement disorders is a promising field.

The case is well described but I have several comments to make:

- Do the authors have information on other similar cases treated with dronabinol in which no improvement (or perhaps secondary effects) were noted? If so, please comment in order to avoid "publication bias".

- Is the mechanism of action of the parkinsonism isquemic? Perhaps the toxicity could be due to other mechanisms (toxic, inflammatory...) Could other "over the counter" substances contribute to the toxicity?

- The authors comment on the lack of structured data on the neurological exploration before treatment. Gait improvement is based on the subjective experience alone. However, could this improvement be quantitatively reflected (Eg. was able to walk unaided, use of support, falls...). If not, then the abstract and conclusions could be overstated. Please correct.

- The improvement was noted after two months. Please comment why the delay, since the effect should have happened earlier.

- Some information on the text should be clarified (was the patient six months in intensive care or was that the total time of hospitalization?). As well is repeated twice in the same sentence. Please correct. The examination was done after two months twice (in the text, not in the table), please correct.
There is some evidence (RCT and good reviews) in the use of CBM in mov disorders. Please consider adding further references. I believe that the case report should be of interest to the readers and should be indexed with some changes.

Is the background of the case's history and progression described in sufficient detail?
Yes

Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?
Yes

Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?
Yes

Is the case presented with sufficient detail to be useful for other practitioners?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Clinical research. Cannabinoids.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 09 Oct 2020
Natalia Szejko, Medical University of Warsaw, Warsaw, Poland

Thank you so much for your valuable comments, we would like to address them below. We have also submitted the new version of the manuscript in the effort to address your comments.

As for other cases of the movement disorders treated with cannabis based medicine, there is already extensive evidence in this area, reporting also about the side effects. We discuss it in the paper, but have included more references and more extensive description, as suggested.

When it comes to the exact mechanism of ischemia in this case, it is not entirely clear. However, we suspect it was both toxic and secondary due to vasoconstriction.

We have updated the information about the gait improvement, as the patient experienced less falls after treatment with dronabinol.

We would like to comment on the time of assessments. The first follow-up was performed
after two months and we do not consider it too long, taking into consideration previous reports, this is an adequate time of evaluation.

We have checked the manuscript for the timing and updated it accordingly.

Finally, we have included more references reporting about the use of CBM in treatment of movement disorders.

**Competing Interests:** No competing interests were disclosed.